| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 173.97% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 03/21/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/17/2020 | 721.92% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
What is the target price for Cyclo Therapeutics (CYTH)?
The latest price target for Cyclo Therapeutics (NASDAQ: CYTH) was reported by Maxim Group on September 27, 2023. The analyst firm set a price target for $4.00 expecting CYTH to rise to within 12 months (a possible 173.97% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cyclo Therapeutics (CYTH)?
The latest analyst rating for Cyclo Therapeutics (NASDAQ: CYTH) was provided by Maxim Group, and Cyclo Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Cyclo Therapeutics (CYTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclo Therapeutics was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating Cyclo Therapeutics (CYTH) correct?
While ratings are subjective and will change, the latest Cyclo Therapeutics (CYTH) rating was a upgraded with a price target of $0.00 to $4.00. The current price Cyclo Therapeutics (CYTH) is trading at is $1.46, which is within the analyst's predicted range.